HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications

This article was originally published in The Rose Sheet

Executive Summary

Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.

You may also be interested in...



Boots' Symptoms Claim For Dual Defence Not A Prevention Pitch – UK Regulator

Boots UK’s display ad for its Dual Defense cold and flu symptom nasal spray was unlikely to deceive consumers to think it could prevent infection, UK Advertising Standards Authority says, which found that text in a poster ad sufficiently "conceptualized" the claim.

Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review

Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.

Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review

Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel